🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Have you wondered if there is a genetic component to your pulmonary fibrosis (PF) diagnosis? Join us for “Genetics and PF: Understanding the Benefits of Genetic Counseling." Date: Saturday, July 13 Time: 10:00 am CT Register Today!

Fibroblasts are everywhere in our tissue as structural cells, yet we are only beginning to understand them. Today in nature, we report that lung-specialized alveolar fibroblasts orchestrate lung homeostasis, inflammation, and fibrosis. 🧵👇(1/n) nature.com/articles/s4158…

A free but temporary link to our article: rdcu.be/dNlNc Non-temporary link: nature.com/articles/s4158…

Excellent final talk of the #TTSummit24 from Christine Garcia Columbia University discussing the genetics of pulmonary fibrosis with an emphasis on #TBD. Team Telomere

'Proteomic Aging Clock': landmark new paper from Austin Argentieri and colleagues using Olink Proteomics data in the UK Biobank. The paper and our podcast with Austin are out today! nature.com/articles/s4159… Well done to all authors from Broad Institute, MassGeneral Medicine, Oxford Population Health (OxPop)!

Is this the MOST important #CureIPF paper of the year? “Lung cell transplantation for pulmonary fibrosis” Kudos Drs Milman Krentsis, Zheng, Reisner & team for this groundbreaking effort! #CurePF4All #ScienceMatters science.org/doi/10.1126/sc…

Absolutely groundbreaking stuff. This is literally science fiction. science.org/doi/10.1126/sc…

#NEWS: We’re excited to announce that our Phase III trial in people living with idiopathic pulmonary fibrosis (IPF) met its primary endpoint.     Learn more here: bit.ly/47JWDoB

Time for the best ILD conference/day camp at #ICLAF2024!

Fine dining with exceptional company #ICLAF2024

Rare variants and survival of patients with idiopathic pulmonary fibrosis medrxiv.org/cgi/content/sh… #medRxiv

Delighted to share our new study led by Aitana Alonso González evaluating the association of rare variants in telomere and non-telomere monogenic adult-onset Pulmonary Fibrosis genes and IPF patient survival where we also intersected their effects with #PRS of IPF. medrxiv.org/content/10.110…

Forthcoming guidance will recommend labs report VUS subclasses. We share experience of 4 labs including rates of reclassification of VUS subclasses. By highlighting VUS-high and downplaying VUS-low, this will be game-changing for dx genetic testing. buff.ly/3Cpx5RL

Million Veteran Program & FinnGen teams are pleased to release v1 meta-analysis of MVP, FinnGen and UKBB GWAS data. This first version includes ~300 binary disease definitions across >1.5 M individuals. Browse scans at: mvp-ukbb.finngen.fi

Important paper just out from the Cardoso Lab! #mustread! Morphogenesis and regeneration share a conserved core transition cell state program that controls lung epithelial cell fate: Developmental Cell cell.com/developmental-…

UK Biobank to run proteomics in 600,000 peripheral blood samples from all 500,000 participants‼️ 👉Olink HT for 5,400 proteins 👉Data releases for 250,000+50,000 repeated measurements to start in 2026 Such a major resource for drug & biomarker discovery💊📈

Excited to share the HIF2 story in Science Translational Medicine. Its been a long time coming. science.org/doi/10.1126/sc… also appreciate the write-up in the VUMC reporter highlighting our group and potential. news.vumc.org/2025/01/08/stu… jon kropski Vanderbilt PSTP/Harrison Society

We're thrilled to present ESM3 in Science Magazine. ESM3 is a generative language model that reasons over the three fundamental properties of proteins: sequence, structure, and function. Today we're making ESM3 available free to researchers worldwide via the public beta of an API

On April 15th at 2pm ET, join our ATS G&G Section for a Journal Club on Convergent and Divergent Immune Aberrations in COVID-19, post-COVID-19-Interstitial Lung Disease, and Idiopathic Pulmonary Fibrosis! Register here: thoracic.zoom.us/meeting/regist…

Original Article: Nerandomilast in Patients with Progressive Pulmonary Fibrosis (FIBRONEER-ILD phase 3 trial) nej.md/436a8g4 #ATS2025 | American Thoracic Society (ATS)